Pharsight

Drugs that contain Pegcetacoplan

1. Drug name - EMPAVELI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169307 APELLIS PHARMS Potent compstatin analogs
Nov, 2027

(5 years from now)

US7989589 APELLIS PHARMS Compstatin analogs with improved activity
Dec, 2027

(5 years from now)

US7888323 APELLIS PHARMS Potent compstatin analogs
Dec, 2027

(5 years from now)

US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(10 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(11 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(11 years from now)

CN101400692B APELLIS PHARMS Effective C3 Complement Inhibin Analogue
Nov, 2026

(4 years from now)

CN102977191A APELLIS PHARMS Effective C3 Complement Inhibin Analogue
Nov, 2026

(4 years from now)

CN106188239A APELLIS PHARMS Effective Compstatin Analog
Nov, 2026

(4 years from now)

CN102977191B APELLIS PHARMS Effective C3 Complement Inhibin Analogue
Nov, 2026

(4 years from now)

CN106188239B APELLIS PHARMS Compstatin Analog Effectively
Nov, 2026

(4 years from now)

CN101400692A APELLIS PHARMS Potent C3 Complement Inhibin Analogues
Nov, 2026

(4 years from now)

CN103687867A APELLIS PHARMS Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Uses Thereof
May, 2032

(9 years from now)

CN103687867B APELLIS PHARMS Cell Reactivity, Release Or Targeting Of Compstatin Analogues And Uses Thereof
May, 2032

(9 years from now)

CN107050422A APELLIS PHARMS Cell Reactivity, Release Or Targeting Of Compstatin Analogues And Uses Thereof
May, 2032

(9 years from now)

CN107050422B APELLIS PHARMS Cell-Reactive, Long-Acting Or Targeted Compstatin Analogues And Uses Thereof
May, 2032

(9 years from now)

CN105051057B APELLIS PHARMS Cell Reactivity, Release Or Targeting Of Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

CN105051057A APELLIS PHARMS Cell Reactive, Long-Acting Or Targeting Camp Statin Analogue And Related Composition And Method
Nov, 2033

(11 years from now)

IN270620B APELLIS PHARMS Potent Compstatin Analogs
Nov, 2026

(4 years from now)

IN200805567P1 APELLIS PHARMS Potent Compstatin Analogs
Nov, 2026

(4 years from now)

IN381491B APELLIS PHARMS Cell Reactive Long Acting Or Targeted Compstatin Analogs And Uses Thereof
May, 2032

(9 years from now)

IN201310061P1 APELLIS PHARMS Cell Reactive Long Acting Or Targeted Compstatin Analogs And Uses Thereof
May, 2032

(9 years from now)

IN201505048P1 APELLIS PHARMS Cell- Reactive , Long -Acting ,Or Targeted Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

IN363846B APELLIS PHARMS Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP2311479B1 APELLIS PHARMS Compstatin Analogs With Improved Activity
Sep, 2023

(11 months from now)

EP1549333B1 APELLIS PHARMS Compstatin Analogues With Improved Activity
Sep, 2023

(11 months from now)

EP1549333A4 APELLIS PHARMS Compstatin Analogs With Improved Activity
Sep, 2023

(11 months from now)

EP1549333A1 APELLIS PHARMS Compstatin Analogues With Improved Activity
Sep, 2023

(11 months from now)

EP2311480A1 APELLIS PHARMS Compstatin Analogs With Improved Activity
Sep, 2023

(11 months from now)

EP2311480B1 APELLIS PHARMS Compstatin Analogs With Improved Activity
Sep, 2023

(11 months from now)

EP2311479A1 APELLIS PHARMS Compstatin Analogs With Improved Activity
Sep, 2023

(11 months from now)

EP2377878A1 APELLIS PHARMS Potent Compstatin Analogs
Nov, 2026

(4 years from now)

EP1960422A2 APELLIS PHARMS Potent Compstatin Analogs
Nov, 2026

(4 years from now)

EP2377877B1 APELLIS PHARMS Potent Compstatin Analogs
Nov, 2026

(4 years from now)

EP2377878B1 APELLIS PHARMS Potent Compstatin Analogs
Nov, 2026

(4 years from now)

EP2377877A1 APELLIS PHARMS Potent Compstatin Analogs
Nov, 2026

(4 years from now)

EP1960422B1 APELLIS PHARMS Potent Compstatin Analogs
Nov, 2026

(4 years from now)

EP2593431A2 APELLIS PHARMS N-Sulfonylbenzamides As Inhibitors Of Voltage-Gated Sodium Channels
Jul, 2031

(8 years from now)

EP2593431B1 APELLIS PHARMS N-Sulfonylbenzamides As Inhibitors Of Voltage-Gated Sodium Channels
Jul, 2031

(8 years from now)

EP2707384B1 APELLIS PHARMS Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Uses Thereof
May, 2032

(9 years from now)

EP2707384A4 APELLIS PHARMS Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Uses Thereof
May, 2032

(9 years from now)

EP2707384A1 APELLIS PHARMS Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Uses Thereof
May, 2032

(9 years from now)

EP3660033A1 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP2920201A4 APELLIS PHARMS Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP2920201A2 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP2920201B1 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP3660033B1 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP3660033B9 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040107 APELLIS PHARMS Dosing regimens and related compositions and methods Apr, 2038

(15 years from now)

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan; treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan every three days; treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1080MG/20ML (54MG/ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.